Corey Goodman receives 40,400 ALX Oncology (ALXO) stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
ALX Oncology Holdings Inc. reported an insider equity award to director and 10% owner Corey S. Goodman. On January 20, 2026, Goodman received a stock option covering 40,400 shares of common stock with an exercise price of $1.32 per share, expiring on January 19, 2036.
The option vests in 12 equal monthly installments beginning on February 20, 2026, meaning the award becomes fully vested over one year. Following this transaction, Goodman beneficially owned 40,400 derivative securities directly in the form of this stock option.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
GOODMAN COREY S
Role
Director, 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 40,400 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 40,400 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
Who is the insider involved in this ALXO Form 4 filing?
The insider is Corey S. Goodman, who is reported as both a director and a 10% owner of ALX Oncology Holdings Inc.
What type of security did Corey S. Goodman receive from ALX Oncology (ALXO)?
Corey S. Goodman received a stock option (right to buy) derivative security linked to ALX Oncology Holdings Inc. common stock.
What is the exercise price and expiration date of the ALXO stock option granted to Corey S. Goodman?
The option has an exercise price of $1.32 per share and an expiration date of January 19, 2036.
When does the ALX Oncology stock option granted to Corey S. Goodman vest?
The shares subject to the option vest in 12 equal monthly installments beginning on February 20, 2026.
How many derivative securities does Corey S. Goodman own after this ALXO transaction?
After this transaction, Corey S. Goodman beneficially owned 40,400 derivative securities, all directly held as this stock option.